Clinical Advances by the MGH Department of Radiation Oncology



The unambiguous goal of the MGH Department of Radiation Oncology is to work intensively to substantially increase the proportion of treated patients who are free of tumor and of treatment-related morbidity. There is acute awareness of the high incidence of cancer each year and the fact that we do not achieve our goal of cure in a significant proportion of patients. Thus, we are definitely sensitive to the fact that there are many questions to be posed and that the answering of those questions requires imaginative and thoughtful laboratory and clinical research. Importantly, there is no ambiguity that time is moving on without the slightest delay. The need for critical questions and the relentless progress of time are clearly illustrated by Fig. 1.


Local Control Radiation Oncology Planning Target Volume Proton Beam Uveal Melanoma 


  1. 1.
    Alm El-Din MA, Hughes KS, Finkelstein DM, et al. Breast cancer after treatment of Hodgkin’s lymphoma: risk factors that really matter. Int J Radiat Oncol Biol Phys. 2009;73(1):69–74.PubMedGoogle Scholar
  2. 2.
    Arvold ND, Lessell S, Bussiere M, et al. Visual outcomes and tumor control after conformal radiotherapy for patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys. 2009;75(4):1166–72.PubMedGoogle Scholar
  3. 3.
    Barker FG 2nd, Butler WE, Lyons S, et al. Dose-volume prediction of radiation-related complications after proton beam radiosurgery for cerebral arteriovenous malformations. J Neurosurg. 2003;99(2):254–63.PubMedGoogle Scholar
  4. 4.
    Batchelor TT, Sorenson AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83–95.PubMedGoogle Scholar
  5. 5.
    Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010;28(17):2817–23.PubMedGoogle Scholar
  6. 6.
    Biggs PJ, Wang CC. An intra-oral cone for an 18 MeV linear accelerator. Int J Radiat Oncol Biol Phys. 1982; 8(7):1251–6.PubMedGoogle Scholar
  7. 7.
    Chakravarti A, Compton CC, Shellito PC, et al. Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. Ann Surg. 1999;230(1):49–54.PubMedGoogle Scholar
  8. 8.
    Chan AW, Liebsch NJ. Proton radiation therapy for head and neck cancer. J Surg Oncol. 2008;97(8):697–700.PubMedGoogle Scholar
  9. 9.
    Chan AW, Tarbell NJ, Black PM, et al. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery. 2000;47(3):623–31.PubMedGoogle Scholar
  10. 10.
    Chan AW, Black P, Ojemann RG, et al. Stereotactic radiotherapy for vestibular schwannomas: favorable outcome with minimal toxicity. Neurosurgery. 2005; 57(1):60–70.PubMedGoogle Scholar
  11. 11.
    Choi C, Carey R. Small cell anaplastic carcinoma of lung. Reappraisal of current management. Cancer. 1976;37(6):2651–7.PubMedGoogle Scholar
  12. 12.
    Choi CH, Suit HD. Evaluation of rapid radiation treatment schedules utilizing two treatment sessions per day. Radiology. 1975;116(3):703–7.PubMedGoogle Scholar
  13. 13.
    Choi NC, Carey RW. Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small-cell lung carcinoma: an update. Int J Radiat Oncol Biol Phys. 1989;17(2):307–10.PubMedGoogle Scholar
  14. 14.
    Choi NC, Doucette JA. Improved survival of patients with unresectable non-small-cell bronchogenic carcinoma by an innovated high-dose en-bloc radiotherapeutic approach. Cancer. 1981;48(1):101–9.PubMedGoogle Scholar
  15. 15.
    Choi NC, Carey RW, Kaufman SD, et al. Small cell carcinoma of the lung. A progress report of 15 years’ experience. Cancer. 1987;59(1):6–14.PubMedGoogle Scholar
  16. 16.
    Choi NC, Herndon JE 2nd, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 1998;16(11):3528–36.PubMedGoogle Scholar
  17. 17.
    Choi NC, Fischman AJ, Niemierko A, et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;54(4):1024–35.PubMedGoogle Scholar
  18. 18.
    Cochran DM, Yock TI, Adams JA Radiation dose to the lens during craniospinal irradiation-an improvement in proton radiotherapy technique. Int J Radiat Oncol Biol Phys. 2008;70(5):1336–42.PubMedGoogle Scholar
  19. 19.
    Coen JJ, Zietman AL, Thakral H et al. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002;20(15):3199–205.PubMedGoogle Scholar
  20. 20.
    del Carmen MG, McIntyre JF, Fuller AF, et al. Intraoperative radiation therapy in the treatment of pelvic gynecologic malignancies: a review of fifteen cases. Gynecol Oncol. 2000;79(3):457–62.PubMedGoogle Scholar
  21. 21.
    DeLaney T, Liebsch N, Pedlow F, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys. 2009;74(3):732–9.PubMedGoogle Scholar
  22. 22.
    DeLaney TF, Chen GT, Mauceri TC, et al. Intraoperative dural irradiation by customized 192iridium and 90yttrium brachytherapy plaques. Int J Radiat Oncol Biol Phys. 2003;57(1):239–45.PubMedGoogle Scholar
  23. 23.
    DeLaney TF, Spiro IJ, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003;56(4):1117–27.PubMedGoogle Scholar
  24. 24.
    DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys. 2005;61(2):492–8.PubMedGoogle Scholar
  25. 25.
    DeLaney TF, Kepka L, Goldberg SI, et al. Radiation therapy for control of soft-tissue sarcomas resected with positive margins. Int J Radiat Oncol Biol Phys. 2007;67(5):1460–9.PubMedGoogle Scholar
  26. 26.
    Dey BR, Shaffer J, Yee AJ, et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2007;40(1):19–27.PubMedGoogle Scholar
  27. 27.
    Efstathiou JA, Zietman AL, Kaufman DS, et al. Bladder-sparing approaches to invasive disease. World J Urol. 2006;24(5):517–29.PubMedGoogle Scholar
  28. 28.
    Fitzek MM, Thornton AF, Rabinov JD, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg. 1999;91(2):251–60.PubMedGoogle Scholar
  29. 29.
    Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys. 2003;57(5):1382–91.PubMedGoogle Scholar
  30. 30.
    Gierga DP, Riboldi M, Turcotte JC, et al. Comparison of target registration errors for multiple image-guided techniques in accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2008;70(4):1239–46.PubMedGoogle Scholar
  31. 31.
    Goitein M, Miller T. Planning proton therapy of the eye. Med Phys. 1983;10(3):275–83.PubMedGoogle Scholar
  32. 32.
    Gragoudas E, Li W, Goitein M, Lane AM, et al. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002;120(12):1665–71.PubMedGoogle Scholar
  33. 33.
    Gragoudas ES, Lane AM, Regan S, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol. 2000;118(6):773–8.PubMedGoogle Scholar
  34. 34.
    Gunderson L, Tepper J. Clinical radiation oncology. Philadelphia, PA: Churchill Livingstone; 2000.Google Scholar
  35. 35.
    Gunderson L, Willett C, Harrison L, et al. Intraoperative Irradiation: techniques and results. Totowa, NJ: Humana; 1999.Google Scholar
  36. 36.
    Gunderson LL, Shipley WU, Suit HD, et al. Intraoperative irradiation: a pilot study combining external beam photons with “boost” dose intraoperative electrons. Cancer. 1982;49(11):2259–66.PubMedGoogle Scholar
  37. 37.
    Gunderson LL, Hoskins RB, Cohen AC, et al. Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys. 1983;9(7):965–75.PubMedGoogle Scholar
  38. 38.
    Hagan MP, Winter KA, Kaufman DS, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57(3):665–72PubMedGoogle Scholar
  39. 39.
    Hoffman KE, Hong TS, Zietman AL, Russell AH. External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis. Cancer. 2008;112(4):943–9.PubMedGoogle Scholar
  40. 40.
    Holmes G, Schulz M. Therapeutic radiology. Philadelphia, PA: Lea and Febiger; 1950.Google Scholar
  41. 41.
    Hong TS, Craft DL, Carlsson F, et al. Multicriteria optimization in intensity-modulated radiation therapy treatment planning for locally advanced cancer of the pancreatic head. Int J Radiat Oncol Biol Phys. 2008;72(4):1208–14.PubMedGoogle Scholar
  42. 42.
    Hoskins RB, Gunderson LL, Dosoretz DE, et al. Adjuvant postoperative radiotherapy in carcinoma of the rectum and rectosigmoid. Cancer. 1985;55(1):61–71.PubMedGoogle Scholar
  43. 43.
    Hug EB, Devries A, Thornton AF, et al. Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neurooncol. 2000;48(2):151–60.PubMedGoogle Scholar
  44. 44.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66.PubMedGoogle Scholar
  45. 45.
    Karakoyun-Celik O, Norris CM Jr, Tishler R, et al. Definitive radiotherapy with interstitial implant boost for squamous cell carcinoma of the tongue base. Head Neck. 2005;27(5):353–61.PubMedGoogle Scholar
  46. 46.
    Kepka L, Suit HD, Goldberg SI, et al. Results of radiation therapy performed after unplanned surgery (without re-excision) for soft tissue sarcomas. J Surg Oncol. 2005;92(1):39–45.PubMedGoogle Scholar
  47. 47.
    Kepka L, DeLaney TF, Suit HD, et al. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2005;63(3):852–9.PubMedGoogle Scholar
  48. 48.
    Kjellberg RN, Kliman B. Bragg peak proton treatment for pituitary-related conditions. Proc R Soc Med. 1974;67(1):32–2.PubMedGoogle Scholar
  49. 49.
    Kjellberg RN, Shintani A, Franz AG, et al. Proton-beam therapy in acromegaly. N Engl J Med. 1968;278(13):689–95.PubMedGoogle Scholar
  50. 50.
    Kjellberg RN, Hanamura T, Davis KR, et al. Bragg-peak proton-beam therapy for arteriovenous malformations of the brain. N Engl J Med. 1983;309(5):269–74.PubMedGoogle Scholar
  51. 51.
    Kozak K, Adams J, Krejcarek S, et al. A dosimetric comparison of proton and intensity modulated photon radiation therapy for pediatric parameningeal rhabdomyosarcomas. Int J Radiat Oncol Biol Phys. 2009;74(1):179–86.PubMedGoogle Scholar
  52. 52.
    Kozak KR, Katz A, Adams J, et al. Dosimetric comparison of proton and photon three-dimensional, conformal, external beam accelerated partial breast irradiation techniques. Int J Radiat Oncol Biol Phys. 2006;65(5):1572–8.PubMedGoogle Scholar
  53. 53.
    Kozak KR, Smith BL, Adams J, et al. Accelerated partial-breast irradiation using proton beams: initial clinical experience. Int J Radiat Oncol Biol Phys. 2006;66(3):691–8.PubMedGoogle Scholar
  54. 54.
    Kozak KR, Kachnic LA, Adams J, et al. Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment. Int J Radiat Oncol Biol Phys. 2007;68(5):1557–66.PubMedGoogle Scholar
  55. 55.
    Krejcarek SC, Grant PE, Henson JW, et al. Physiologic and radiographic evidence of the distal edge of the proton beam in craniospinal irradiation. Int J Radiat Oncol Biol Phys. 2007;68(3):646–9.PubMedGoogle Scholar
  56. 56.
    Krengli M, Hug EB, Adams JA, et al. Proton radiation therapy for retinoblastoma: comparison of various intraocular tumor locations and beam arrangements. Int J Radiat Oncol Biol Phys. 2005;61(2):583–93.PubMedGoogle Scholar
  57. 57.
    Landry J, Tepper JE, Wood WC, et al. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys. 1990;19(6):1357–62.PubMedGoogle Scholar
  58. 58.
    Lawenda BD, Taghian AG, Kachnic LA, et al. Dose-volume analysis of radiotherapy for T1N0 invasive breast cancer treated by local excision and partial breast irradiation by low-dose-rate interstitial implant. Int J Radiat Oncol Biol Phys. 2003;56(3):671–80.PubMedGoogle Scholar
  59. 59.
    Lawenda BD, Gagne HM, Gierga DP, et al. Permanent alopecia after cranial irradiation: dose-response relationship. Int J Radiat Oncol Biol Phys. 2004;60(3):879–87.PubMedGoogle Scholar
  60. 60.
    Macdonald SM, Taghian AG. Partial-breast irradiation: towards a replacement for whole-breast Irradiation? Expert Rev Anticancer Ther. 2007;7(2):123–34.PubMedGoogle Scholar
  61. 61.
    MacDonald SM, Safai S, Trofimov A, et al. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys. 2008;71(4):979–86.PubMedGoogle Scholar
  62. 62.
    Mori S, Wolfgang J, Lu HM, Schneider R, et al. Quantitative assessment of range fluctuations in charged particle lung irradiation. Int J Radiat Oncol Biol Phys. 2008;70(1):253–61.PubMedGoogle Scholar
  63. 63.
    Nguyen PL, Chakravarti A, Finkelstein DM, et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005;23(7):1507–13.PubMedGoogle Scholar
  64. 64.
    Orezzoli JP, Russell AH, Oliva E, et al. Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol. 2008;110(3):336–44.PubMedGoogle Scholar
  65. 65.
    Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002;296(5574):1883–6.PubMedGoogle Scholar
  66. 66.
    Pai HH, Thornton A, Katznelson L, et al. Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 2001;49(4):1079–92.PubMedGoogle Scholar
  67. 67.
    Park L, DeLaney TF, Liebsch NJ, et al. Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys. 2006;65(5):1514–21.PubMedGoogle Scholar
  68. 68.
    Patel S, Adams JA, Chan AW. Nasopharynx. In: DeLaney T, Kooy H, eds. Proton and heavier charged particle radiotherapy. Philadelphia, PA: Lippincott, Williams and Wilkins; 2008:197–205.Google Scholar
  69. 69.
    Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.PubMedGoogle Scholar
  70. 70.
    Pommier P, Liebsch NJ, Deschler DG, et al. Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132(11):1242–9.PubMedGoogle Scholar
  71. 71.
    Pommier P, Krengli M, Thornton A, et al. Paranasal sinus and nasal cavity. In: DeLaney T, Kooy H, eds. Proton and heavier charged particle radiotherapy. Philadelphia, PA: Lippincott, Williams and Wilkins; 2008:187–97.Google Scholar
  72. 72.
    Rosenberg A, Nielsen G, Keel S, et al. Chondrosarcoma of the base of the skull: a clinicopathological study of 200 cases with emphasis on it’s distinction from chordoma. Am J Surg Pathol. 1999;23:1370–8.PubMedGoogle Scholar
  73. 73.
    Ruka W, Taghian A, Gioioso D, et al. Comparison between the in vitro intrinsic radiation sensitivity of human soft tissue sarcoma and breast cancer cell lines. J Surg Oncol. 1996;61(4):290–4.PubMedGoogle Scholar
  74. 74.
    Russell WO, Cohen J, Enzinger F, et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer. 1977;40(4):1562–70.PubMedGoogle Scholar
  75. 75.
    Sher DJ, Wittenberg E, Taghian AG, et al. Partial breast irradiation versus whole breast radiotherapy for early-stage breast cancer: a decision analysis. Int J Radiat Oncol Biol Phys. 2008;70(2):469–76.PubMedGoogle Scholar
  76. 76.
    Shih HA, Harisinghani M, Zietman AL, et al. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys. 2005;63(4):1262–9.PubMedGoogle Scholar
  77. 77.
    Shipley WU, Tepper JE, Prout GR Jr, et al. Proton radiation as boost therapy for localized prostatic carcinoma. JAMA. 1979;241(18):1912–5.PubMedGoogle Scholar
  78. 78.
    Shipley WU, Coombs LJ, Einstein AB Jr, et al. Cisplatin and full dose irradiation for patients with invasive bladder carcinoma: a preliminary report of tolerance and local response. J Urol. 1984;132(5):899–903.PubMedGoogle Scholar
  79. 79.
    Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995;32(1):3–12.PubMedGoogle Scholar
  80. 80.
    Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002;60(1):62–7.PubMedGoogle Scholar
  81. 81.
    Shipley WU, Zietman AL, Kaufman DS, et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates – the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol. 2005;15(1):36–41, 290–4.PubMedGoogle Scholar
  82. 82.
    Spear MA, Jennings LC, Mankin HJ, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys. 1998;40(3):637–45.PubMedGoogle Scholar
  83. 83.
    Spiro IJ, Gebhardt MC, Jennings LC, et al. Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. Semin Oncol. 1997;24(5):540–6.PubMedGoogle Scholar
  84. 84.
    Suit HD, Russell WO, Martin RG. Management of patients with sarcoma of soft tissue in an extremity. Cancer. 1973;31(5):1247–55.PubMedGoogle Scholar
  85. 85.
    Suit HD, Russell WO, Martin RG. Sarcoma of soft tissue: clinical and histopathologic parameters and response to treatment. Cancer. 1975;35(5):1478–83.PubMedGoogle Scholar
  86. 86.
    Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004;22(21):4247–54.PubMedGoogle Scholar
  87. 87.
    Taghian AG, Assaad SI, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 2001;93(23):1806–11.PubMedGoogle Scholar
  88. 88.
    Taghian AG, Abi-Raad R, Assaad SI, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol. 2005;23(9):1951–61.PubMedGoogle Scholar
  89. 89.
    Taghian AG, Jeong JH, Mamounas EP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006;24(24):3927–32.PubMedGoogle Scholar
  90. 90.
    Taghian AG, Kozak KR, Doppke K, et al. Initial dosimetric experience using simple three-dimensional conformal external-beam accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2006;64(4):1092–9.PubMedGoogle Scholar
  91. 91.
    Talcott JA, Rossi C, Shipley WU, et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA. 2010;303(11):1046–53.PubMedGoogle Scholar
  92. 92.
    Tepper JE, Shipley WU, Warshaw AL, et al. The role of misonidazole combined with Intraoperative radiation therapy in the treatment of pancreatic carcinoma. J Clin Oncol. 1987;5(4):579–84.PubMedGoogle Scholar
  93. 93.
    Terahara A, Niemierko A, Goitein M, et al. Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. Int J Radiat Oncol Biol Phys. 1999;45:351–8.PubMedGoogle Scholar
  94. 94.
    Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007;69(2):444–53.PubMedGoogle Scholar
  95. 95.
    Tsai HK, Katz MS, Coen JJ, et al. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer. Urology. 2006;68(6):1188–92.PubMedGoogle Scholar
  96. 96.
    Wang C. Radiation therapy for head and neck neoplasms. 3rd ed. New York, NY: Wiley-Liss; 1997.Google Scholar
  97. 97.
    Wang CC. Altered fractionation of radiation therapy for gynecologic cancers. Cancer. 1987; 60(8 suppl):2064–7.PubMedGoogle Scholar
  98. 98.
    Wang CC, Doppke KP, Biggs PJ. Intra-oral cone radiation therapy for selected carcinomas of the oral cavity. Int J Radiat Oncol Biol Phys. 1983;9(8):1185–9.PubMedGoogle Scholar
  99. 99.
    Weber DC, Chan AW, Lessell S, et al. Visual outcome of accelerated fractionated radiation for advanced sinonasal malignancies employing photons/protons. Radiother Oncol. 2006; 81(3):243–9.PubMedGoogle Scholar
  100. 100.
    Wenkel E, Thornton AF, Finkelstein D, et al. Benign meningioma: partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48(5):1363–70.PubMedGoogle Scholar
  101. 101.
    Willers H, Beck-Bornholdt HP. Origins of radiotherapy and radiobiology: separation of the influence of dose per fraction and overall treatment time on normal tissue damage by Reisner and Miescher in the 1930s. Radiother Oncol. 1996;38(2):171–3.PubMedGoogle Scholar
  102. 102.
    Willett CG, Linggood RM, Stracher MA, et al. The effect of the respiratory cycle on mediastinal and lung dimensions in Hodgkin’s disease. Implications for radiotherapy gated to respiration. Cancer. 1987;60(6):1232–7.PubMedGoogle Scholar
  103. 103.
    Willett CG, Linggood RM, Leong JC, et al. Stage IA to IIB mediastinal Hodgkin’s disease: three-dimensional volumetric assessment of response to treatment. J Clin Oncol. 1988;6(5):819–24PubMedGoogle Scholar
  104. 104.
    Willett CG, Suit HD, Tepper JE, et al. Intraoperative electron beam radiation therapy for retroperitoneal soft tissue sarcoma. Cancer. 1991;68(2):278–83.PubMedGoogle Scholar
  105. 105.
    Willett CG, Ooi CJ, Zietman AL, et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol Phys. 2000;46(4):995–8.PubMedGoogle Scholar
  106. 106.
    Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145–7.PubMedGoogle Scholar
  107. 107.
    Yock T, Schneider R, Friedmann A, et al. Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys. 2005;63(4):1161–8.PubMedGoogle Scholar
  108. 108.
    Yock TI, Tarbell NJ. Technology insight: proton beam radiotherapy for treatment in pediatric brain tumors. Nat Clin Pract Oncol. 2004;1(2):97–103; quiz 1 p following 111. Erratum in: Nat Clin Pract Oncol. 2005;2(4):222.PubMedGoogle Scholar
  109. 109.
    Yock TI, Krailo M, Fryer CJ, et al. Local control in pelvic Ewing sarcoma: analysis from INT-0091 – a report from the Children’s Oncology Group. J Clin Oncol. 2006;24(24):3838–43. Erratum in: J Clin Oncol. 2006;24(30):4947.PubMedGoogle Scholar
  110. 110.
    Zhang M, Mukherjee N, Bermudez RS, et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate. 2005;64(3):293–302.PubMedGoogle Scholar
  111. 111.
    Zietman AL. Evidence-based medicine, conscience-based medicine, and the management of low-risk prostate cancer. J Clin Oncol. 2009;27(30):4935–6.PubMedGoogle Scholar
  112. 112.
    Zietman AL, Dallow K, McManus P, et al. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology. 1996;47(2):236–9.PubMedGoogle Scholar
  113. 113.
    Zietman AL, Nakfoor BM, Prince EA, et al. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am. 1997;3(1):31–6.PubMedGoogle Scholar
  114. 114.
    Zietman AL, Prince E, Nakfoor BEAM, et al. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys. 1997;38(5):1067–70.PubMedGoogle Scholar
  115. 115.
    Zietman AL, Zehr EM, Shipley WU. The long-term effect on PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer. Int J Radiat Oncol Biol Phys. 1999;43(4):715–8.PubMedGoogle Scholar
  116. 116.
    Zietman AL, Thakral HJ, Wilson L, et al. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol. 2001;166(5):1702–6.PubMedGoogle Scholar
  117. 117.
    Zietman AL, Chung CS, Coen JJ, et al. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol. 2004;171(1):210–4.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Radiation OncologyMassachusetts General HospitalBostonUSA

Personalised recommendations